Compare FWRD & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | PRAX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.1M | 7.2B |
| IPO Year | 1993 | 2020 |
| Metric | FWRD | PRAX |
|---|---|---|
| Price | $26.11 | $291.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $34.33 | ★ $373.79 |
| AVG Volume (30 Days) | 401.1K | ★ 615.7K |
| Earning Date | 02-25-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,496,734,000.00 | $7,463,000.00 |
| Revenue This Year | $3.18 | N/A |
| Revenue Next Year | $4.39 | $12,467.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.54 | ★ 364.98 |
| 52 Week Low | $9.79 | $26.70 |
| 52 Week High | $35.47 | $317.72 |
| Indicator | FWRD | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 62.92 |
| Support Level | $25.12 | $268.78 |
| Resistance Level | $26.29 | $317.72 |
| Average True Range (ATR) | 0.68 | 13.98 |
| MACD | -0.09 | -3.34 |
| Stochastic Oscillator | 85.15 | 50.94 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.